Log in to search using one of your social media accounts:

 

Th1/17 Hybrid CD4+ Cells Are Expanded in Bronchial Alveolar Lavage Fluid from Leukemia Patients with Checkpoint Inhibitor-Induced Pneumonitis

Leukemia, checkpoint inhibitors, pneumonitis, Th1/17 hybrid CD4+ cells, bronchial alveolar lavage
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research

Related Links:

Haematological malignancies (leukaemias, lymphomas and myeloma) are complex cancers that are relatively common, affect all ages and have divergent outcomes. Although the symptom burden of these diseases is com...
Source: BMC Palliative Care - Category: Palliative Care Authors: Tags: Research article Source Type: research
Conditions:   Non Hodgkin Lymphoma;   Multiple Myeloma;   Chronic Lymphocytic Leukemia;   Diffuse Large B Cell Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma Interventions:   Genetic: JCAR017;   Genetic: JCARH125 Sponsor:   Juno Therapeutics, Inc. Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
d R Abstract In normal cells, aberrant oncogene expression leads to the accumulation of cytotoxic metabolites, including reactive oxygen species (ROS), which can cause oxidative DNA-damage and apoptosis as an intrinsic barrier against neoplastic disease. The c-Myc oncoprotein is overexpressed in many lymphoid cancers due to c-myc gene amplification and/or 8q24 chromosomal translocations. Intriguingly, p53 is a downstream target of c-Myc and hematological malignancies, such as adult T-cell leukemia/lymphoma (ATL), frequently contain wildtype p53 and c-Myc overexpression. We therefore hypothesized that p53-regulated...
Source: Virology - Category: Virology Authors: Tags: Virology Source Type: research
Prognostic factors of second allogeneic stem cell transplantation (allo-SCT2) in 78 patients with relapsed AML after first transplantation were explored. Those were poor cytogenetic risk at diagnosis, circulating blast ≥ 20% at relapse, duration from first transplant to relapse
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Complete molecular response (CMR) and overall survival (OS) in patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) treated with front-line chemotherapy plus ponatinib versus earlier-generation tyrosine kinase inhibitors (TKIs) were compared in a meta-analysis and meta-regression. Patients treated with front-line ponatinib versus earlier-generation treatments were more likely to achieve CMR and had higher rates of 3-year OS.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Multiple myeloma (MM), characterized by malignant plasma cells in the bone marrow (BM), is consistently preceded by asymptomatic pre-malignant stage monoclonal gammopathy of undetermined significance (MGUS). These MGUS patients have an annual risk of 1% to progress to MM. Clinical, imaging and genomic (genetic and epigenetic) factors were identified, whose presence increased the risk of progression from MGUS to MM. This systematic review summarizes the currently identified clinical, imaging and genomic biomarkers, suggested to increase the progression risk or demonstrated to be differential expressed/presence between both cohorts of patients.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
Identifying risk factors influencing post-HSCT relapse outcome in acute leukemia is essential. 43 patients were studied. Older age and failure to achieve CR following treatment were associated with inferior OS. Female sex, extramedullary relapse and absence of post-relapse GVHD were associated with lower CR. Absence of extramedullary relapse, treatment with DLI and occurrence of post-relapse GVHD were associated with higher NRM.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
This article is protected by copyright. All rights reserved.
Source: British Journal of Dermatology - Category: Dermatology Authors: Tags: Research Letter Source Type: research
This article is protected by copyright. All rights reserved. PMID: 29451690 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
There is an increasing frequency of double-hit diffuse large B-cell lymphomas, which represent at least 4% of all diffuse large B-cell lymphoma (DLBCL).1 These double-hit lymphomas (DHLs) have been defined by the 2016 WHO classification as high-grade diffuse large B cell lymphomas with translocations involving c-myc in combination with translocations of bcl-2 and/or bcl-6.2
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
More News: Leukemia | Lymphoma | Myeloma